TNF Pharmaceuticals, Inc. (TNFA) - Dilution Analysis

10-Q filing | 8.1M shares outstanding

10-K filing | 7.9M shares outstanding

8-K filing: Q/C Technologies, Inc. entered into a consulting agreement with Chelsea Voss, granting her restricted stock units and stock options in exchange for consulting services.

10-Q filing | 4.2M shares outstanding

S-3 filing: This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to an aggregate of 6,511,799 shares of our common stock.

8-K filing: Q/C Technologies, Inc. issued warrants to purchase up to 400,000 shares of common stock to Z-List Media, Inc. as part of a consulting agreement.

8-K filing: TNF Pharmaceuticals, Inc. announces a private placement of Series H convertible preferred stock and warrants, a reverse stock split, and a membership interest purchase agreement. ($7.0M proceeds)

10-Q filing | 14.2M shares outstanding

10-K filing | 10.1M shares outstanding

10-Q filing | 2.8M shares outstanding

8-K filing: TNF Pharmaceuticals, Inc. entered into a Stock Purchase Agreement with Prevail Partners, LLC to sell 283,019 shares of common stock at $2.12 per share for gross proceeds of $600,000. ($0.6M proceeds)

10-Q filing | 2.3M shares outstanding

S-3/A filing: Resale of common stock issuable upon conversion of preferred stock and exercise of warrants.

S-3 filing: This S-3 filing relates to the resale of common stock issuable upon conversion of preferred shares and exercise of warrants.

8-K filing: MyMD Pharmaceuticals, Inc. completed private placements of Series G and Series F-1 Convertible Preferred Stock for aggregate gross proceeds of $14 million on May 23, 2024. ($28.0M proceeds)

8-K filing: MyMD Pharmaceuticals, Inc. entered into Securities Purchase Agreements with accredited investors to sell Series G and Series F-1 Convertible Preferred Stock, along with warrants, in private placements expected to close around May 22, 2024. ($13.9M proceeds)

10-Q filing | 2.1M shares outstanding

10-K filing | 2.2M shares outstanding

8-K filing: Stock split 1-for-30 | Outstanding: 50,900,715 → 2,091,638

10-Q filing | 50.9M shares outstanding

10-Q filing | 44.9M shares outstanding

10-Q filing | 39.8M shares outstanding

10-K filing | 38.8M shares outstanding

8-K filing: The Company entered into a definitive agreement with accredited investors to sell 15,000 shares of Series F Convertible Preferred Stock and warrants to acquire up to 6,651,885 shares of Common Stock in a registered direct offering.

10-Q filing | 39.0M shares outstanding

8-K filing: The company entered into a definitive agreement to sell 1,411,764 shares of common stock in a registered direct offering and issue warrants to purchase up to 1,411,764 shares of common stock in a private placement.

10-Q filing | 38.3M shares outstanding

10-Q filing | 38.1M shares outstanding

10-K filing | 38.1M shares outstanding

10-Q filing | 37.6M shares outstanding

10-Q filing | 37.4M shares outstanding

10-Q filing | 8.8M shares outstanding

S-3/A filing: The filing is an S-3/A amendment to register the resale of common stock by selling stockholders, including shares, pre-funded warrant shares, and investor warrant shares. The company may also offer a combination of securities up to $100,000,000.

8-K filing: Stock split 1-for-2 | Outstanding: 1,738,837 → 869,418

S-3 filing: The filing is an S-3 registration statement for the potential offering of up to $100,000,000 in common stock and preferred stock, and also covers the resale of up to 20,273,989 shares of Common Stock by selling stockholders.

8-K filing: Akers Biosciences entered into a Contribution and Assignment Agreement with Cystron LLC, Oravax Medical, Inc., and Premas Biotech PVT Ltd., contributing assets to Oravax in exchange for 390,000 shares of Oravax stock. Oravax also issued 1,890,000 shares to Oramed in exchange for technology and cash contribution.

10-K filing | 1.7M shares outstanding

8-K filing: Akers Biosciences, Inc. closed a private placement of 9,765,933 shares of its common stock and warrants to purchase 9,765,933 shares of its common stock resulting in aggregate gross proceeds to the Company of approximately $18.1 million. ($18.1M proceeds)

10-Q filing | 1.7M shares outstanding

8-K filing: The closing of the private placement of 9,765,933 shares of common stock and warrants to purchase 9,765,933 shares of common stock resulting in aggregate gross proceeds of approximately $18.1 million is expected to close on or around November 16, 2020. ($18.1M proceeds)

8-K filing: Akers Biosciences, Inc. entered into a merger agreement with MYMD Pharmaceuticals, Inc. and also entered into a Securities Purchase Agreement to sell shares of Akers common stock and warrants in a private placement. ($20.0M proceeds)

S-3 filing: The selling stockholder may offer and resell from time to time up to 500,000 shares of common stock issued pursuant to a Settlement Agreement and General Release.

10-Q filing | 1.7M shares outstanding

8-K filing: Akers Biosciences, Inc. entered into a Securities Purchase Agreement to issue and sell 1,207,744 shares of common stock at $5.67 per share in a registered direct offering, with gross proceeds of approximately $6.8 million, and also agreed to grant the placement agent warrants to purchase up to 96,620 shares of common stock at an exercise price of $7.0875. ($6.8M proceeds)

8-K filing: Akers Biosciences, Inc. entered into a Settlement Agreement and General Release with ChubeWorkx Guernsey Limited, where Akers will deliver 500,000 shares of common stock to ChubeWorkx as consideration for the settlement of claims.

S-3/A filing: This S-3/A filing relates to the potential resale of up to 793,437 shares of common stock by selling stockholders, consisting of shares issued under a Membership Interest Purchase Agreement (MIPA) and shares issuable upon conversion of Series D Convertible Preferred Stock and exercise of warrants.

S-3 filing: The selling stockholders named in this prospectus may use this prospectus to offer and resell from time to time up to 793,437 shares of our common stock

8-K filing: Akers Biosciences, Inc. completed a registered direct offering of 1,366,856 shares of common stock at a price of $3.53 per share, resulting in gross proceeds of approximately $4.825 million before deductions. ($4.83M proceeds)

10-Q filing | 1.7M shares outstanding

8-K filing: Akers Biosciences, Inc. entered into a Securities Purchase Agreement to issue and sell 1,366,856 shares of common stock at $3.53 per share in a registered direct offering, for gross proceeds of approximately $4.825 million, with the closing expected on or about May 18, 2020. ($4.83M proceeds)

8-K filing: Warrants to purchase 1,043,500 shares of Series C Preferred Stock of Akers Biosciences, Inc. were exercised at $4.00 per share and immediately converted into 1,043,500 shares of the Company's common stock, resulting in 4,755,407 shares of common stock outstanding as of April 17, 2020. ($4.17M proceeds)

8-K filing: Akers Biosciences, Inc. entered into a Securities Purchase Agreement to issue and sell 766,667 shares of common stock at $6.00 per share in a registered direct offering, for gross proceeds of approximately $4.6 million. ($4.6M proceeds)

S-3/A filing: The Registrant is registering an indeterminate aggregate principal amount and number of securities of each identified class of securities up to a proposed aggregate offering price of $25,000,000, which may be offered from time to time in unspecified numbers and at indeterminate prices, and as may be issuable upon conversion, redemption, repurchase, exchange, or exercise of any securities registered hereunder, including under any applicable anti-dilution provisions.

10-K filing | 0.5M shares outstanding